ID21979A - Metode penggunaan inhibitor-inhibitor siklooksigenase-2 sebagai zat-zat anti-angiogenik - Google Patents

Metode penggunaan inhibitor-inhibitor siklooksigenase-2 sebagai zat-zat anti-angiogenik

Info

Publication number
ID21979A
ID21979A IDW990379A ID990379A ID21979A ID 21979 A ID21979 A ID 21979A ID W990379 A IDW990379 A ID W990379A ID 990379 A ID990379 A ID 990379A ID 21979 A ID21979 A ID 21979A
Authority
ID
Indonesia
Prior art keywords
inhibitors
cyhoxoxigage
angiogenic substance
angiogenic
substance
Prior art date
Application number
IDW990379A
Other languages
English (en)
Indonesian (id)
Inventor
Jamie L Masferrer
Amiram Raz
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of ID21979A publication Critical patent/ID21979A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW990379A 1996-11-19 1997-11-19 Metode penggunaan inhibitor-inhibitor siklooksigenase-2 sebagai zat-zat anti-angiogenik ID21979A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3140496P 1996-11-19 1996-11-19

Publications (1)

Publication Number Publication Date
ID21979A true ID21979A (id) 1999-08-19

Family

ID=21859277

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW990379A ID21979A (id) 1996-11-19 1997-11-19 Metode penggunaan inhibitor-inhibitor siklooksigenase-2 sebagai zat-zat anti-angiogenik

Country Status (19)

Country Link
EP (1) EP0941080A2 (no)
JP (1) JP2001505564A (no)
KR (1) KR20000053362A (no)
CN (1) CN1247470A (no)
AU (1) AU730211B2 (no)
BR (1) BR9713522A (no)
CA (1) CA2270469C (no)
CZ (1) CZ176899A3 (no)
ID (1) ID21979A (no)
IL (1) IL129604A (no)
NO (1) NO992309D0 (no)
NZ (1) NZ335853A (no)
PL (2) PL194717B1 (no)
RO (1) RO118566B1 (no)
RU (1) RU2268716C2 (no)
SK (1) SK59999A3 (no)
TR (1) TR199901703T2 (no)
UA (1) UA70294C2 (no)
WO (1) WO1998022101A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
KR20010110310A (ko) * 1998-12-23 2001-12-12 로저 에이. 윌리암스 종양 치료에 사이클로옥시게나제-2 억제제와 하나 이상의항종양제를 조합치료법으로서 사용하는 방법
DE60023119T2 (de) * 1999-03-10 2006-07-20 G.D. Searle Llc Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere
CN1181819C (zh) * 1999-07-29 2004-12-29 图拉列克股份有限公司 使用五氟苯磺酰胺的综合疗法
US6914069B2 (en) 2000-05-19 2005-07-05 Applied Research Systems Ars Holding N.V. Pharmaceutically active compounds and methods of use
AU2002234165A1 (en) 2000-11-03 2002-05-27 Tularik, Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
KR100686537B1 (ko) * 2001-12-28 2007-02-27 씨제이 주식회사 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
BR0312744A (pt) * 2002-07-17 2005-04-26 Warner Lambert Co Associação de um inibidor carboxìlico alostérico da metaloproteinase-13 de matriz com um inibidor selectivo da ciclooxigenase-2, à excepção do celecoxib ou valdecoxib
KR100484525B1 (ko) * 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
AT504159A1 (de) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc Verwendung von proteasen
RU2475257C1 (ru) * 2011-06-22 2013-02-20 Людмила Николаевна Третьяк Средство для повышения адаптируемости организма к экстремальным условиям
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0764644A1 (en) * 1993-01-15 1997-03-26 G.D. Searle & Co. Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a gastrointestinal condition
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
CZ294630B6 (cs) * 1993-11-30 2005-02-16 G. D. Searle & Co. Substituované pyrazolylbenzensulfonamidy pro léčení zánětů
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
ATE232856T1 (de) * 1994-12-21 2003-03-15 Merck Frosst Canada Inc Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

Also Published As

Publication number Publication date
UA70294C2 (en) 2004-10-15
BR9713522A (pt) 2000-03-21
PL191793B1 (pl) 2006-07-31
EP0941080A2 (en) 1999-09-15
JP2001505564A (ja) 2001-04-24
NZ335853A (en) 2002-02-01
PL194717B1 (pl) 2007-06-29
IL129604A0 (en) 2000-02-29
IL129604A (en) 2004-08-31
SK59999A3 (en) 2000-01-18
PL333370A1 (en) 1999-12-06
RO118566B1 (ro) 2003-07-30
CA2270469C (en) 2007-04-10
TR199901703T2 (xx) 2000-07-21
WO1998022101A3 (en) 1998-06-25
AU730211B2 (en) 2001-03-01
AU7298298A (en) 1998-06-10
NO992309L (no) 1999-05-12
CA2270469A1 (en) 1998-05-28
CZ176899A3 (cs) 1999-10-13
RU2268716C2 (ru) 2006-01-27
NO992309D0 (no) 1999-05-12
CN1247470A (zh) 2000-03-15
WO1998022101A2 (en) 1998-05-28
KR20000053362A (ko) 2000-08-25

Similar Documents

Publication Publication Date Title
ID17411A (id) Metoda penyiapan-benda benda penyerap
DK1121192T3 (da) Fremgangsmåde til homogenisering
IS8368A (is) Ný aðferð
DK1085981T3 (da) Fremgangsmåde til emballering
FI965268A0 (fi) Menetelmä moniarvoisten alkoholien valmistamiseksi
ID21979A (id) Metode penggunaan inhibitor-inhibitor siklooksigenase-2 sebagai zat-zat anti-angiogenik
ID26990A (id) Metode pembuatan dimetilnaftalena
DE69733883D1 (de) Verfahren zur zugabe von borverbindungen
EE04154B1 (et) Omeprasooli valmistamise meetod
DE69733962D1 (de) Plasma-ätzmethode
ID22098A (id) Metode menghilangkan coret-coretan
DK0874822T3 (da) Ny fremgangsmåde til fremstilling
DK0987356T3 (da) Fremgangsmåde til trækning
ID20733A (id) Metode pembuatan sikat
DE69737237D1 (de) Verfahren zur trockenätzung
ID16838A (id) Komposisi dekafluoropentana
ID18300A (id) Metoda penemperan
DE69708229T2 (de) Muster-Herstellungsverfahren
ID17941A (id) Metode penerapan komposisi pembuat marka jalan
ID20291A (id) Asam-asam oksobutirat tersubstitusi sebagai penghamba-penghambat matriks metaloproteasa
ID19540A (id) Metode pembuatan turunan-turunan benzofenon
ID17419A (id) Komposisi dekafluoropentana
ID23019A (id) Metode pembuatan turunan nitroguadinin
ATE218559T1 (de) Verfahren zur monoacylierung von hydroxytaxanen
EE9900404A (et) Arüülaminotriasolopüridiinide valmistamise meetod